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A B S T R A C T
The aim of this study is to investigate the differences of clinical and laboratory parameters between patients with
JAK2-V617F positive myeloproliferative neoplasms (MPNs) and JAK2 wild type MPNs. DNA was isolated from periph-
eral blood granulocytes of 106 patients treated at Rijeka University Hospital Center: 41 with polycythemia vera (PV), 43
with essential thrombocythemia (ET), 9 with primary myelofibrosis (PMF) and 13 with myeloproliferative neoplasm-
-unclassifiable (MPN-u). The JAK2-V617F mutation was detected using allele specific PCR. Laboratory and clinical pa-
rameters were obtained from patient’s medical records. The JAK2-V617F mutation was detected in 69% (73/106) patients
with MPNs. The results revealed significantly different prevalence of JAK2-V617F mutation, between MPNs entities:
88% in PV, 58% in ET, 56% in PMF and 54% in MPNs-unclassified disorders. The JAK2-V617F mutation significantly
correlated with higher leukocyte count and alkaline phosphatase score in ET group and with higher platelets count, leu-
kocyte alkaline phosphatase score and serum lactate dehydrogenase in PV group. Vascular events were associated with
elevated platelets count in whole MPNs group, with higher platelets and leukocyte count in ET and with splenomegaly in
PV patients. Clinical and laboratory data revealed significant contribution of JAK2-V617F mutation to the development
of clinical phenotype in patients with distinct subgroups of MPNs.
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Introduction
The classic Ph-negative myeloproliferative neoplasms
(MPNs) include various disorders such as polycythemia
vera (PV), essential thrombocythemia (ET), and primary
myelofibrosis (PMF). Their classification and the criteria
for diagnosis have been recently updated by the Word
Health Organization (WHO)1. The MPNs are clonal he-
matopoietic stem cell disorders characterized by prolifer-
ation of one or more myeloid cell lineages in the bone
marrow2–5. The genetic cause of these diseases was un-
known until 2005, when several independent groups
demonstrated that most patients with PV, ET and PMF
acquire a mutation affecting the gene for Janus tyrosine
kinase 2. The mutation corresponds to a single-nucleo-
tide change of JAK2 nucleotide 1849, in exon 14, resulting
in a unique valine (V) to phenylalanine (F) substitution
at amino acid position 617 of the protein (JAK2-V617F)6–8.
This acquired mutation occurs in the pseudokinase do-
main of JAK2 in hematopoietic cells and is responsible
for the constitutive activation of molecular signaling
pathways leading to an uncontrolled phosphorylation of
substrate molecules including signal transducers and ac-
tivators of transcription (STAT proteins, so called JAK
-STAT signaling). The result is cell proliferation inde-
pendent of normal growth factor control9. JAK2-V617F
mutation confirmed the presence of a clonal disorder and
is an important diagnostic marker10,11. Thus, we investi-
gated the prevalence of JAK2-V617F mutation in our
MPNs patients treated at Clinical Hospital Center Rijeka.
We have also examined the correlation of JAK2-V617F
mutation with changes in hematologic and biochemical
parameters and with incidence of splenomegaly and
thromboembolic complications in MPNs patients.
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The study included 106 patients with a known or sus-
pected myeloproliferative disorders treated at Depart-
ment of Hematology, Internal Medicine Clinic, Clinical
Hospital Center Rijeka. The diagnoses of PV, ET, PMF
and MPN-u were made according to 2008 WHO criteria,
based on peripheral blood counts and bone marrow his-
tology. Bone marrow biopsy specimens, taken from iliac
crests, have been fixed in Scheffer’s fixative for 12 to 24
hours and decalcified in Osteodec (Bio-Optica Italy). Spe-
cimens were sectioned and stained using hematoxylin-
-eosin, Giemsa, PAS reaction, Gomory stain for reticular
and iron staining. All slides were reviewed by two certi-
fied pathologists. Laboratory and clinical data included
hemoglobin and hematocrit level, white blood cells and
platelet count, leukocyte alkaline phosphatase score, se-
rum lactate dehydrogenase, presence of splenomegaly
and vascular events. The study was approved by the Eth-
ical committee of the institutional review board of the
Rijeka University Hospital Center. All the patients en-
rolled in this study signed consent form for anonymous
use of laboratory and medical history data.
DNA isolation and Polymerase Chain
Reaction (PCR) method
Blood was drawn from 106 patients in collection tube
for polymorphonuclear cells separation (Vacutainer CPT
4.0 mL Ficoll, BD, Franklin Lakes, USA). Genomic DNA
was isolated from polymorphonuclear cells using Nucleo-
Spin	Blood kit (Macharey-Nagel, Duren, Germany) ac-
cording to the manufacturer’s instructions. The JAK2
--V617F mutation was determined using allele specific
PCR as described previously6. Briefly, 1 L of isolated
genomic DNA was amplified in 35 cycle PCR reaction at
annealing temperature of 58 °C with 1 mol/L of common
reverse primer (5'/ CTG AAT AGT CCT ACA GTG TTT
TCA GTT TCA 3') and 0.5 mol/L of two forward primers
(forward specific 5/ AGC ATT TGG TTT TAA ATT ATG
GAG TAT ATT 3' and forward internal control 5' ATC
TAT AGT CAT GCT GAA AGT AGG AGA AAG 3'). First
forward primer is specific for the mutant allele (a sin-
gle-nucleotide G to T alteration at position 1849 of JAK2
gene), giving 203 bp product, and second amplifies 364
bp products from both mutant and wild type alleles and
serves as internal PCR control. Described method is veri-
fied by using quality control JAK2 V617F DNA through
collaboration with Laboratory for Molecular Pathology,
Institute of Pathology, Medical University, Graz, Austria.
Statistical analysis
We used the t-test and Wilcoxon Mann-Whitney test
for comparison of continuous variables and the two-
-tailed Fisher exact test for categorical variables. p val-
ues below or equal to 0.05 were considered significant
and accepted only for statistical power of more then 0.8
for b2 values. Statistical data were collected and orga-
nized using MS Excel and analyzed using R statistical
software (The R Foundation for Statistical Computing).
Results
Clinical and laboratory findings of patients with
MPNs and MPNs entities are shown in Table 1. Repre-
sentative bone marrow biopsies of distinct MPNs entities
are shown in Figure 1. The JAK2-V617F mutation was
found in 73/106 (69%) patients with MPNs, 36/41 (88%)
with PV, 25/43 (58%) with ET, 5/9 (56%) with PMF and
7/13 (54%) with MPN-u. The prevalence of JAK2-V617F
mutation was significantly different between MPNs sub-
types, ET and PV (p=0.003). Splenomegaly, vascular
events, lactate dehydrogenase and leukocyte alkaline
phosphatase were not significantly different within dis-
tinct MPNs subgroups, while the values of hemoglobin
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Fig. 1. Representative bone marrow biopsy specimens from iliac
crests. (A) polycithemya vera, (B) essential thrombocytosis, and
(C) idiopathic myelofibrosis. Larger microphotographs magnifi-
cation x100, smaller microphotographs magnification x400.
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(p<0.001), hematocrit (p<0.001), platelets (p=0.021)
and leukocytes counts (p=0.018) were significantly dif-
ferent between ET and PV. At diagnosis, JAK2-V617F
positive MPNs patients were characterized by higher val-
ues of hemoglobin, hematocrit, leucocytes counts and
leukocyte alkaline phosphatase score (in all cases p<
0.001; Table 2). There was no significant correlation be-
tween JAK2-V617F mutation and splenomegaly and vas-
cular events (p=0.188 and p=0.342, respectively) in
whole group of MPNs patients. ET patients with JAK2-
-V617F mutation demonstrated significantly higher leu-
kocyte count and alkaline phosphatase score (p=0.005,
p<0.001), while PV patients with this mutation were
characterized with higher platelets counts, higher alka-
line phosphatase and lactate dehydrogenase score (p=
0.006, p=0.059, p=0.03). Thromboembolic and bleeding
complications were present in 26/106 (25%) patients with
MPNs or more specifically in 32% with PV, 26% with ET,
11% with PMF and 8% with MPN-u (Table 1). Majority
of those patients were JAK2-V617F positive (20/26; 77%;
Table 2.). Vascular events were associated with platelets
count (p=0.006) in whole MPNs group, with platelets
and leukocyte count in ET (p=0.033, p=0.014, respec-
tively), and with splenomegaly in PV patients (p=0.017),
as shown in Table 3.
Discussion and Conclusion
Results from our study showed that a single somatic
activating mutation JAK2-V617F was identified in most
patients with PV and in about half of patients with ET or
PMF. PV, ET and PMF share common clinical features
and belong to clonal disorders of multipotent progeni-
tors, underlying many similarities between these disorders.
Literature data revealed that prevalence of JAK2-V617F
mutation in PV ranges from 65 to 100%, in ET from 28 to
80%, in PMF from 33 to 85% and in MPN-u from 38 to
75%12. These differences could be explained with vari-
able number of analyzed cases and the differences in sen-
sitivity and specificity of methods applied for detection of
JAK2- V617F mutation13,14.
Our study revealed that the patients carrying JAK2-
-V617F mutation displayed leukocytosis and higher level
of hemoglobin and hematocrit than mutation negative
patients, as it was reported by previously published stu-
dies15–18. Furthermore, we demonstrated that higher leu-
kocyte count, elevated serum lactate dehydrogenase and
alkaline phosphatase score are associated with presence
of JAK2-V617F mutation, a finding that indicates acti-
vated myelopoiesis, which is also suggested in several
previous published studies17,19. Although some studies
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TABLE 1
CLINICAL AND LABORATORY PARAMETERS IN MYELOPROLIFERATIVE NEOPLASMS (MPNS) AND DISTINCT ENTITIES,














Positive, N (%) 73 (69) 25 (58) 36 (88) 5 (56) 7 (54) 0.005
Negative, N (%) 33 (31) 18 (42) 5 (12) 4 (44) 6 (46) 0.003*
Hemoglobin (g/L) (X±SD) 149.3±31.5 135±20.5 175.9±13.9 124.4±24.9 122.5±43.2 <0.001*
Hematocrit (X±SD) 0.5±0.1 0.4±0.1 0.6±0.1 0.4±0.1 0.4±0.1 <0.001*
Platelets (x109/L), median (range) 602 (80–2692) 682 (423–2692) 520 (135–1224) 560 (80–1776) 403 (91–915) <0.001
>1000
109/L, N (%) 19 (18) 12 (28) 3 (7) 1 (11) 0 0.021*
<1000
109/L, N (%) 86 (82) 31 (72) 38 (93) 8 (89) 12 (100)
WBC (
109/L), median (range) 10.6 (4.1–31) 9.4 (4.1–29) 11 (5.8–18.5) 10.1 (4.3–16.7) 14.4 (6.4–31) 0.098
>10
109/L, N (%) 56 (53) 17 (40) 27 (66) 2 (22) 8 (62) 0.018*
<10
109/L, N (%) 49 (47) 26 (60) 14 (34) 7 (78) 5 (38)
Alkaline phosphatase (U/L),
median (range)
61.5 (0–338) 68 (0–332) 82 (5–338) 34 (19–41) 40.5 (2–108) 0.444*
Lactate dehydrogenase (U/L),
median (range)
238 (68–1463) 225.5 (90–546) 248 (68–984) 433 (220–1463) 215.5 (77–575) 0.557*
Splenomegaly (>3 cm)
Yes, N (%) 36 (34) 12 (28) 14 (34) 2 (22) 8 (62) 0.151
No, N (%) 70 (66) 31 (72) 27 (66) 7 (78) 5 (38) 0.638*
Vascular events
Yes, N (%) 26 (25) 11 (26) 13 (32) 1 (11) 1 (8) 0.313
No, N (%) 80 (75) 32 (74) 28 (68) 8 (89) 12 (92) 0.631*
* indicate p values of differences evaluated by Fisher exact test between MPNs subtypes, essential thrombocythemia (ET) and poly-
cythemia vera (PV). In the platelets andWBC columns the total number of patients is not exact (106) because some data are missing.
U:\coll-antropolo\coll-antro-3-2012\12096 Nacinovic.vp
26. rujan 2012 13:56:29
Color profile: Disabled
Composite  Default screen
A. Na~inovi} Duleti} et al.: JAK2-V617F Mutation in Myeloproliferative Neoplasms, Coll. Antropol. 36 (2012) 3: 859–865
862
TABLE 2
CLINICAL AND LABORATORY PARAMETERS ACCORDING TO THE PRESENCE OF JAK2-V617F MUTATION IN MYELOPROLIFERATIVE





Hemoglobin (g/L) (X±SD) 156.8±27.9 133.2±33.4 <0.001*
Hematocrit (X±SD) 0.5±0.1 0.4±0.1 <0.001*
Platelets (x109/L) median (range) 616.5 (80-2692) 548 (91-1512) 0.192†
>1000x109/L, N (%) 14 (19) 5 (15) 0.786‡
<1000x109/L, N (%) 58 (81) 28 (85)
WBC (x109/L), (X±SD) 11.8±4.2 9.5±5 <0.001†
>10x109/L, N (%) 46 (64) 10 (30) <0.001‡
<10x109/L, N (%) 26 (36) 23 (70)
Alkaline phosphatase (U/L), median (range) 88 (2-338) 21.5 (0-108) <0.001†
Lactate dehydrogenase (U/L), median (range) 245 (68-984) 220 (77-1463) 0.905†
Splenomegaly (>3 cm)
Yes, N (%) 28 (38) 8 (24) 0.188‡
No, N (%) 45 (62) 25 (76)
Vascular events
Yes, N (%) 20 (27) 6 (18) 0.342‡
No, N (%) 53 (73) 27 (82)
ET (No=43)
Hemoglobin (g/L) (X±SD) 140.7±21 131.2±19.1 0.138*
Hematocrit (X±SD) 0.4±0.1 0.4±0.04 0.3*
Platelets (x109/L) (median, range) 721 (423-2692) 651 (476-1512) 0.118†
>1000x109/L, N (%) 9 (36) 3 (17) 0.911‡
<1000x109/L, N (%) 16 (64) 15 (83)
WBC (x109/L), (X±SD) 12.1±5.7 8.1±2.3 0.005†
>10x109/L, N (%) 14 (56) 3 (17) 0.013‡
<10x109/L, N (%) 11 (44) 15 (83)
Alkaline phosphatase (U/L), median (range) 97 (28-332) 15 (0-85) <0.001†
Lactate dehydrogenase (U/L), median (range) 228 (96-417) 220 (90-546) 0.963†
Splenomegaly (>3 cm)
Yes, N (%) 9 (36) 3 (17) 0.191‡
No, N (%) 16 (64) 15 (83)
Vascular events
Yes, N (%) 9 (36) 2 (11) 0.086‡
No, N (%) 16 (64) 16 (89)
PV (No=41)
Hemoglobin (g/L) (X±SD) 177±13.9 168.4±12.5 0.21*
Hematocrit (X±SD) 0.6±0.1 0.5±0.1 0.386*
Platelets (x109/L), (median, range) 546.5 (135-1224) 185 (173-307) 0.006*
>1000x109/L, N (%) 3 (8) 0 1‡
<1000x109/L, N (%) 33 (92) 5 (100)
WBC (x109/L), (X±SD) 11.6±2.9 8.9±2.3 0.064†
>10x109/L, N (%) 25 (69) 2 (40) 0.317‡
<10x109/L, N (%) 11 (31) 3 (60)
Alkaline phosphatase (U/L), median (range) 96.5 (5-338) 19 (14-69) 0.059†
Lactate dehydrogenase (U/L), median (range) 257.5 (68-984) 148 (137-170) 0.03†
Splenomegaly (>3 cm)
Yes, N (%) 13 (36) 1 (20) 0.645‡
No, N (%) 23 (64) 4 (80)
Vascular events
Yes, N (%) 10 (28) 3 (60) 0.304‡
No, N (%) 26 (72) 2 (40)
*Student t-test; †Mann-Whitney Wilcoxon test; ‡Fisher exact test
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TABLE 3
CLINICAL AND LABORATORY PARAMETERS ACCORDING TO THE VASCULAR EVENTS IN MYELOPROLIFERATIVE NEOPLASMS





Hemoglobin (g/L) (X±SD) 158.2±30.2 146.4±31.6 0.099*
Hematocrit (X±SD) 0.5±0.1 0.5±0.1 0.78*
Platelets, median (range) 719 (173-1527) 565 (80-2692) 0.017†
>1000x109/L, N (%) 10 (38) 9 (11) 0.006‡
<1000x109/L, N (%) 16 (62) 70 (89)
WBC(X±SD) 12.3±4.8 10.8±4.5 0.108†
>10x109/L, N (%) 17 (65) 39 (49) 0.179‡
<10x109/L, N (%) 9 (35) 40 (51)
Alkaline phosphatase (U/L), median (range) 76 (14-295) 53 (0-338) 0.075†
Lactate dehydrogenase (U/L), median (range) 257.5 (68-627) 230 (77-1463) 0.980†
Splenomegaly (>3 cm)
Yes, N (%) 12 (46) 24 (30) 0.156‡
No, N (%) 14 (54) 56 (70)
JAK2 V617
Positive, N (%) 20 (77) 53 (66) 0.342‡
Negative, N (%) 6 (23) 27 (34)
ET (No=43)
Hemoglobin (g/L) (X±SD) 139.8±24.6 135.5±19.4 0.624*
Hematocrit (X±SD) 0.4±0.1 0.4±0.04 0.833*
Platelets, median (range) 1020 (573-1527) 661 (423-2692) 0.033†
>1000x109/L, N (%) 7 (64) 5 (16) 0.005‡
<1000x109/L, N (%) 4 (36) 27 (84)
WBC (X±SD) 13.5±6.6 9.3±3.8 0.016†
>10x109/L, N (%) 8 (73) 9 (28)
<10x109/L, N (%) 3 (27) 23 (72) 0.014‡
Alkaline phosphatase (U/L), median (range) 77 (33-177) 44 (0-332) 0.285†
Lactate dehydrogenase (U/L), median (range) 277 (134-412) 212 (90-546) 0.085†
Splenomegaly (>3 cm)
Yes, N (%) 4 (36) 8 (25)
No, N (%) 7 (64) 24 (75) 0.467‡
JAK2-V617F
Positive, N (%) 9 (82) 16 (50)
Negative, N (%) 2 (18) 16 (50) 0.086‡
PV (No=41)
Hemoglobin (g/L) (X±SD) 177.8±18 175.1±11.8 0.628*
Hematocrit (X±SD) 0.6±0.1 0.6±0.1 0.852*
Platelets, median (range) 603 (173-1224) 498 (135-1177) 0.363†
>1000x109/L, N (%) 2 (15) 1 (4)
<1000x109/L, N (%) 11 (85) 27 (96) 0.232‡
WBC (X±SD) 11.6±3.05 11.1±3 0.604†
>10x109/L, N (%) 9 (69) 18 (64)
<10x109/L, N (%) 4 (31) 10 (36) 1‡
Alkaline phosphatase (U/L), median (range) 99 (14-295) 82 (5-338) 0.94†
Lactate dehydrogenase (U/L), median (range) 212 (68-336) 253.5 (124-984) 0.16†
Splenomegaly (>3 cm)
Yes, N (%) 8 (62) 6 (21)
No, N (%) 5 (38) 22 (79) 0.017‡
JAK2-V617F
Positive, N (%) 10 (77) 26 (93)
Negative, N (%) 3 (23) 2 (7) 0.304‡
*Student t-test; †Mann-Whitney Wilcoxon test; ‡Fisher exact test
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found correlation between JAK2-V617F mutation and
splenomegaly others failed to find such association20–22.
Our results are in agreement with those studies which
were not able to confirm this association.
The clinical course of the MPNs is characterized by
thrombotic and hemorrhagic events that significantly
impact prognosis and quality of life. It is generally ac-
cepted that MPNs are a risk factor for thrombosis21–23.
Although epidemiologic and clinical studies identify the
MPNs as thrombophilic conditions, the pathogenesis of
thrombosis in MPNs is not elucidated because it is multi-
factorial and complex disorder21. Portal vein thrombosis
can be the first and only sign, presenting latent or
masked MPNs24. The incidence of thrombosis and hem-
orrhage at diagnosis for PV varies in average, from 5% to
39% and for ET, between 11% and 37%22. Our study has
shown that 25% of patients with MPNs demonstrate vas-
cular events. From 26 patients with thromboembolic
complications 77% were JAK2-V617F mutation positive
making this mutation the strongest possible predictor
for thrombosis. Vascular events were associated with
higher platelets count in whole MPNs group. Patients
with ET demonstrated high platelets and leukocyte counts
and 82% of patients were positive for JAK2-V617F muta-
tion. The meta-analysis of large number of ET cases,
with thrombosis, showed JAK2-V617F positive patients
to be at a two-fold higher risk of developing thrombosis25.
Our study revealed that splenomegaly was significantly
associated with thromboembolic complications in 62% of
PV patients. JAK2-V617F mutation was present in 77%
patients suffering from thrombosis. There is no final
agreement on the role of JAK2-V617F mutation in over-
all risk of thrombosis or bleeding in MPNs patients20–23.
In a large study of 1213 patients with PV, thrombosis
(both arterial and venous) occurred in 41% of patients
and splenomegaly was present in approximately 70% of
patients with PV26. Harrison suggested that progressive
or symptomatic splenomegaly revealed high risk of throm-
bosis in patients with PV27.
Recently, Carobbio et al. and Tefferi and Elliott, re-
ported that leukocytosis, but not thrombocytosis, has
been identified as a potential risk factor for thrombo-
embolic complications in PV and ET24,28. Although the
pathogenetic background leading to hypercoagulability
is not clearly defined, it is suggested that the activated
neutrophils may play a central role in thrombogenesis29.
In conclusion, the JAK2-V617F mutation was fre-
quently detected in our patients with MPNs in accor-
dance with literature data, and therefore should be in-
corporated into the clinical work up of patients with
suspected MPNs. Furthermore, analysis should focus on
JAK2-V617F allele burden (copy number) as well as mu-
tation genotype (gene dosage) to determine genetic back-
ground necessary to evaluate disease phenotype.
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MUTACIJA JAK2-V617F JE POVEZANA S KLINI^KO-LABORATORIJSKIM OBILJE@JIMA
MIJELOPROLIFERATIVNIH NEOPLAZMI
S A @ E T A K
Cilj ovog rada je istra`iti razlike izme|u klini~kih i laboratorijskih parametara bolesnika s JAK2-V617F pozitivnim
mijeloproliferativnim novotvorinama (MPN) i bolesnika s MPN-om bez JAK2-V617F mutacije. DNA je izolirana iz
granulocita periferne krvi 106 bolesnika lije~enih u KBC Rijeka: 41 bolesnik s policitemijom verom (PV), 43 s esen-
cijalnom trombocitemijom (ET), 9 s primarnom mijelofibrozom (PMF) i 13 s neklasificiranom mijeloproliferativnom
novotvorinom (MPN-u). JAK2-V617F mutacija je analizirana pomo}u alel specifi~nog PCR-a. Laboratorijski i klini~ki
parametri dobiveni su iz medicinske dokumentacije bolesnika. JAK2-V617F mutacija je utvr|ena u 69% (73/106) boles-
nika s MPN-om. Rezultati su pokazali statisti~ki zna~ajnu razliku u prevalenciji JAK2-V617F mutacije kod bolesnika s
razli~itim MPN entitetima: 88% u PV, 58% u ET, 56% u PMF-u i 54% u neklasificiranomMPN-u. JAK2-V617F mutacija
statisti~ki zna~ajno korelira s leukocitozom i povi{enom alkalnom fosfatazom kod ET oboljelih, a s trombocitozom i
povi{enom razinom leukocitne alkalne fosfataze i serumske laktat dehidrogenaze u oboljelih od PV-a. Vaskularni doga-
|aji su povezani s povi{enim brojem trombocita u cijeloj skupini oboljelih od MPN-a, s povi{enim brojem trombocita i
leukocita u oboljelih od ET-a i sa splenomegalijom u bolesnika s PV-om. Klini~ki i laboratorijski podaci su pokazali
zna~ajnu povezanost JAK2-V617Fmutacije s razvojem klini~kog fenotipa bolesnika u razli~itim podskupinamaMPN-a.
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